Optimal Pharmacological Therapy In Implantable Defibrillator Patients (OPTIC) - Full Text View

Home

Study Topics

Glossary


	Full Text View


	Tabular View


	Contacts and Locations


	Related Studies

Optimal Pharmacological Therapy In Implantable Defibrillator Patients (OPTIC)

This study has been completed.

Sponsors and Collaborators:	Connolly, Stuart, M.D. St. Jude Medical
Information provided by:	Connolly, Stuart, M.D.
ClinicalTrials.gov Identifier:	NCT00257959

Purpose

This is an open parallel design randomized trial of amiodarone plus a beta blocker vs a beta blocker alone vs sotalol for the prevention of ICD shocks in patients receiving an ICD for spontaneous or inducible ventricular tachycardia or fibrillation

Condition	Intervention	Phase
Ventricular Tachycardia	Drug: amiodarone beta blocker sotalol	Phase IV

Genetics Home Reference related topics:

Brugada syndrome short QT syndrome

ChemIDplus related topics:

Amiodarone Amidox Amiodarone hydrochloride Sotalol Sotalol hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study

Further study details as provided by Connolly, Stuart, M.D.:

Primary Outcome Measures:

ICD shock for any cause

Estimated Enrollment:	400
Study Start Date:	January 2001
Estimated Study Completion Date:	October 2004

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria: spontaneous or inducible ventricular tachycardia or fibrillation -

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00257959

Locations


Canada, Ontario
	McMaster University
	Hamilton, Ontario, Canada

Sponsors and Collaborators

Connolly, Stuart, M.D.

St. Jude Medical

Investigators


Principal Investigator:	Stuart Connolly	Hamilton Health Sciences

Principal Investigator:	Stuart Connolly	Hamilton Health Sciences

More Information

Publications of Results:

Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, Thorpe K, Champagne J, Talajic M, Coutu B, Gronefeld GC, Hohnloser SH; Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006 Jan 11;295(2):165-71.

Hohnloser SH, Dorian P, Roberts R, Gent M, Israel CW, Fain E, Champagne J, Connolly SJ. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation. 2006 Jul 11;114(2):104-9. Epub 2006 Jul 3.

Study ID Numbers:	1
First Received:	November 22, 2005
Last Updated:	July 26, 2006
ClinicalTrials.gov Identifier:	NCT00257959
Health Authority:	Canada: Ethics Review Committee

Study placed in the following topic categories:

Heart Diseases

Tachycardia

Tachycardia, Ventricular

Amiodarone

Sotalol

Arrhythmias, Cardiac

Additional relevant MeSH terms:

Vasodilator Agents

Pathologic Processes

Molecular Mechanisms of Pharmacological Action

Therapeutic Uses

Enzyme Inhibitors

Cardiovascular Diseases

Cardiovascular Agents

Anti-Arrhythmia Agents

Pharmacologic Actions

ClinicalTrials.gov processed this record on September 19, 2008